QuidelOrtho Corp (QDEL) reported third-quarter earnings for fiscal 2025, delivering an earnings per share (EPS) of $0.80, surpassing the consensus estimate of $0.47 by $0.33. Revenue matched expectations at $0.7 billion.
The company, headquartered in San Diego, California, operates in the health care sector as a vitro diagnostics firm, employing approximately 6,600 full-time staff. QuidelOrtho specializes in immunoassay and molecular testing, clinical chemistry, and transfusion medicine. Its diverse product offerings include rapid immunoassay tests and diagnostic solutions under various brand names such as AdenoPlus and Lyra.
Management will host an earnings conference call to discuss these results and provide additional insights into business performance.
This earnings report highlights QuidelOrtho's operational performance and financial health, indicating stronger-than-anticipated business fundamentals. Investors are encouraged to review the full earnings release and listen to management commentary for further context on the quarter's performance and future outlook.
Looking ahead, QuidelOrtho is expected to report earnings on August 2, 2026, with an EPS estimate of $0.384 and revenue also projected at $0.7 billion.